“Research use only” peptides and the FDA

“Peptide” is not an approval status

A peptide is a chain of amino acids. Whether a peptide can be lawfully prescribed in the US depends on whether a specific product has been approved, not on the fact that it is a peptide. Several approved medicines are peptides: the Ozempic® label describes semaglutide’s peptide backbone, the Saxenda® label calls liraglutide an analogue of human GLP-1, and the Mounjaro® label says tirzepatide is based on the GIP sequence ^[9][10][11].

Each of those approvals covers a particular product, made to particular standards, with a label that sets out its uses, doses and warnings. The same molecule sold in a different form, by a different maker, does not share that approval. The article on approved peptide medicines gives more examples.

What a “research use only” label means

On its page about unapproved GLP-1 drugs, the FDA says it has sent warnings to companies that were illegally selling unapproved semaglutide, tirzepatide, retatrutide, survodutide or mazdutide under false “for research purposes” or “not for human consumption” labels. Those products went straight to consumers, complete with dosing instructions, for people to use on themselves ^[2].

The FDA urges consumers not to buy such products, describing them as of unknown quality and potentially harmful. It adds that federal law bars retatrutide and cagrilintide from compounding, that neither is an ingredient of any FDA-approved drug, and that neither has been shown safe and effective for any condition ^[2]. It has also warned telehealth companies, ingredient distributors and outsourcing facilities over retatrutide ^[2].

Compounding is a separate route

Some peptides reach patients through compounding pharmacies rather than as finished, approved products. The FDA states that compounded drugs are not FDA approved, and that it does not verify their safety, effectiveness or quality before they are marketed ^[3].

Section 503A of the Food, Drug, and Cosmetic Act sets the rule: a pharmacist or physician may compound from a bulk ingredient only if it complies with a USP or NF monograph where one exists, or, if there is none, is a component of an approved drug, or, failing both, appears on a list the FDA sets by regulation, the 503A bulks list ^[7]. The FDA judges nominations for that list on four criteria: physical and chemical characterisation, safety, evidence of effectiveness, and historical use in compounding, weighed against each other ^[7].

While it evaluates nominations, the FDA sorts them into three categories under an interim policy. It does not intend to act against compounders using category 1 substances, those nominated with enough supporting information for it to evaluate, provided the conditions in its guidance are met. Category 2 holds substances with significant safety risks; category 3 holds nominations made without enough supporting information, which compounders cannot rely on ^[4].

Peptides in the FDA’s category 2 table

• Growth hormone releasing peptide-2 (GHRP-2), for injectable and nasal routes (503B, added 29 September 2023). The FDA notes reports of serious adverse events, including a higher insulin requirement, infection and pancreatitis, though causality has not been established ^[1].
• Growth hormone releasing peptide-6 (GHRP-6) (503B, 29 September 2023) ^[1].
• Ipamorelin acetate (503B, 29 September 2023) ^[1].
• Kisspeptin-10 (503A, 29 September 2023) ^[1].
• The table also lists non-peptide substances, such as ibutamoren mesylate, cesium chloride and domperidone ^[1].

Peptides whose nominations were withdrawn

The same page has a second list: substances previously in category 2 whose nominations were withdrawn by the nominators. The FDA still shows its safety concerns for each. The peptides named there are AOD-9604, BPC-157, cathelicidin LL-37, CJC-1295, dihexa acetate, emideltide (DSIP), epitalon, GHK-Cu (for injectable routes), ipamorelin acetate, KPV, mechano growth factor pegylated (PEG-MGF), Melanotan II, MOTs-C, selank acetate (TP-7), semax (heptapeptide), thymosin-alpha 1 and thymosin beta-4 fragment (LKKTETQ), also known as TB-500 ^[1].

Withdrawal from category 2 does not mean a substance moved to category 1. The FDA’s May 2026 update of its 503A nominations shows how narrow the exceptions are: GHK-Cu was removed from category 1 when its nominations were withdrawn, then added back for non-injectable routes only, after one nominator clarified that it had meant to withdraw only the injectable route ^[5]. The FDA said it intends to consult its advisory committee about GHK-Cu before the end of February 2027 ^[5].

Why the FDA flags these peptides

• Immunogenicity: for many entries, the FDA says the compounded drug may pose a risk of an immune reaction for certain routes because of possible aggregation and peptide-related impurities ^[1].
• Missing safety data: for BPC-157, the FDA says it has no, or only limited, safety information for the proposed routes and lacks enough information to know whether it would cause harm in humans. For TB-500, KPV, MOTs-C and PEG-MGF it found no human exposure data ^[1].
• Reported events: for CJC-1295, the FDA notes serious adverse events including increased heart rate and a systemic vasodilatory reaction; for Melanotan II, published case reports including melanoma and priapism ^[1].
• Unusual building blocks: GHRP-2 and ipamorelin contain unnatural amino acids, which the FDA says makes them harder to characterise ^[1].

The July 2026 advisory committee review

On 23 and 24 July 2026, the FDA asked its Pharmacy Compounding Advisory Committee whether seven peptide ingredients, each in free-base and acetate form, should be placed on the 503A bulks list ^[6]. The original nominations had been withdrawn, but the FDA chose to present the substances anyway ^[7]. In its briefing, the agency proposed that none of them be included ^[7].

What the FDA found on BPC-157

The FDA’s review of BPC-157, dated May 2026, explains its proposal. There is no USP or NF monograph for BPC-157 in either form, and neither is a component of an approved drug ^[8]. The agency judged both forms not well characterised, citing inconsistent naming and missing data on identity, purity, impurities, aggregates and microbial quality, and it could not rule out immune reactions to impurities or aggregated peptide in an injectable product ^[8].

On effectiveness, the FDA concluded that the evidence was insufficient to support BPC-157 as a treatment for ulcerative colitis, the use it was asked to assess, and noted that approved treatments for that condition exist ^[8]. It also found too little clinical safety information to characterise BPC-157’s safety. A search of its adverse event database up to December 2025 retrieved three reports, all involving injected products, and the agency noted that 503A compounders generally do not report adverse events to it ^[8].

Advisory committees give non-binding advice, which the FDA generally follows but is not obliged to ^[6]. The briefing says the agency will not make a final determination until it has considered the committee’s input and finished its reviews ^[7]. When this page was checked on 21 October 2026, the FDA’s meeting page, last updated on 6 August 2026, listed the briefing documents and presentations but no final decision ^[6].

What independent reviews add

A 2025 systematic review of BPC-157 in orthopaedic sports medicine found 36 eligible studies: 35 in animals or the laboratory and one small retrospective clinical study. It found no clinical safety data and warned of possible harm from unregulated manufacturing and contamination ^[13].

A 2026 narrative review of approved and unapproved peptides marketed directly to patients, including BPC-157, TB-500, CJC-1295, ipamorelin and MOTS-c, concluded that many look favourable in animal models but that rigorous human safety data are scarce and there is potential for serious harm ^[14]. Reviews summarise published work; they cannot vouch for what is inside a vial sold online.

Before you consider any of these substances

If you are considering any substance on these lists, the people to ask are a licensed clinician and pharmacist who know your health. For athletes there is a second question: several of the same names, including BPC-157, TB-500 and MOTS-c, are on the World Anti-Doping Agency’s Prohibited List ^[12]. Our article on the WADA Prohibited List covers how sport treats them.

Problems with any medicine, including suspected quality problems, can be reported to the FDA’s MedWatch programme ^[2].

Ozempic® and Saxenda® are registered trademarks of Novo Nordisk A/S. Mounjaro® is a registered trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Novo Nordisk or Eli Lilly, and does not sell or recommend any peptide.